Zynerba Pharma Revenue, Profits - ZYNE Annual Income Statement

Add to My Stocks
$11.57 $0.82 (6.62%) ZYNE stock closing price Jun 22, 2018 (Closing)

ZYNE stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Zynerba Pharma stock price. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. The income statement for ZYNE which shows a YOY revenue decline of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Revenue for year 2017 is $- and has decreased from $- year on year as is evident when you compare the latest figures in the latest Zynerba Pharma profit and loss statement with those of the prior corresponding period. Also see Zynerba Pharma assets and Zynerba Pharma free cash flow for a complete valuation of ZYNE stock.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20172016201520142013
Zynerba Pharma Revenues or Net Sales
-----
Cost Of Goods Sold (COGS)-----
Zynerba Pharma Gross Profit
-----
Research & Development Expense22.8M16.78M7.44M2.4M1.13M
Selling General & Admin Expense10.01M6.43M5.36M4.07M-
Income Before Depreciation Depletion Amortization-32.82M-23.2M-12.53M-5.66M-0.63M
Depreciation Depletion Amortization-----
Non Operating Income--0.2M---
Interest Expense-----
Zynerba Pharma Pretax Income
-32.01M-23.41M-12.52M-5.66M-0.63M
Provision for Income Taxes--0.02M---
MinorityInterest-----
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-32.01M-23.38M-12.55M-5.66M-0.63M
Extraordinary Items & Discontinued Operations-----
Zynerba Pharma Profit/ Loss (Net Income)
-32.01M-23.38M-12.55M-5.66M-0.63M
Average Shares used to compute Diluted EPS12.92M9.07M4.46M--
Average Shares used to compute Basic EPS12.92M9.07M4.46M--
Income Before Nonrecurring Items-32.01M-23.39M-11.21M--
Income from Nonrecurring Items---1.34M--
Zynerba Pharma Earnings Per Share Basic Net
-2.48-2.58-2.82--
Zynerba Pharma Earnings Per Share Diluted Net
-2.48-2.58-2.82--
EPS Diluted Before Nonrecurring Items-2.48-2.58-2.52--
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

It is very helpful to read a report on Zynerba Pharma stock analysis. An investor must check the following items in an income statement:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that ZYNE stock has a topline or revenue of $- for 2017 as per this Zynerba Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. ZYNE stock had a poor bottom line growth.

The income statement is also called the profit and loss statement. Apart from the ZYNE income statement, one can check the Zynerba Pharma historical stock prices to check how the price has moved with time.

Zynerba Pharma Income Statement - Key Financial Ratios

Operating Margin
0
Net Profit Margin
0